Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis Theresa K. WebsterStephanie C. RothSameer A. Patel Review 14 March 2022 Pages: 241 - 251
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer Jason A. MouabbiAmy HassanRachel M. Layman Review 26 March 2022 Pages: 253 - 264
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review Nhu Hanh ToHoang Quy NguyenOn behalf of the TransAtlantic Radiation Oncology Network (TRONE) & Association of Radiotherapy, and Oncology of the Mediterranean Area (AROME) Review 09 April 2022 Pages: 265 - 279
Clinical trial data and emerging strategies: HER2-positive breast cancer Sonia PernasSara M. Tolaney Review 09 April 2022 Pages: 281 - 291
Health care professionals overestimate the risk for locoregional recurrences after breast cancer treatment depending on their specialty Jet W. AnkersmidPauline E. R. SpronkSabine Siesling Preclinical study Open access 13 March 2022 Pages: 293 - 303
PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer Liqiang QiBo SunSu Lu Preclinical Study 24 March 2022 Pages: 305 - 318
The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target Yun-Song YangYi-Xing RenZhi-Ming Shao Preclinical study 25 March 2022 Pages: 319 - 330
Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer Ridho AssidickyUnal Metin TokatOzgur Sahin Preclinical study 25 March 2022 Pages: 331 - 348
PIK3CA-AKT pathway predominantly acts in developing ipsilateral breast tumor recurrence long after breast-conserving surgery Hiroshi NakagomiMasayuki InoueMasao Omata Preclinical study 25 March 2022 Pages: 349 - 359
Multi-omics analyses provide novel biological insights to distinguish lobular ductal types of invasive breast cancers Ambily SivadasVictor C. KokKa-Lok Ng Preclinical study 29 March 2022 Pages: 361 - 379
Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer Yun WuYiqun HanBinghe Xu Clinical trial 16 March 2022 Pages: 381 - 392
Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy Qixing TanQinghong QinChangyuan Wei Clinical trial 18 March 2022 Pages: 393 - 403
B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis Shuai WangXinyan ZhangRuimei Sun Clinical trial 21 March 2022 Pages: 405 - 416
Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen Brittany BychkovskyAlison LawsTari A. King Clinical trial 04 April 2022 Pages: 417 - 427
Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer Linda YeDennis RüngerMaggie L. DiNome Clinical trial 07 April 2022 Pages: 429 - 436
Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer Luc DirixAndy BuysPeter Vermeulen Clinical trial Open access 09 April 2022 Pages: 437 - 444
Trends in surgical treatment of early-stage breast cancer reveal decreasing mastectomy use between 2003 and 2016 by age, race, and rurality Mya L. RobersonHazel B. NicholsWhitney R. Robinson Epidemiology 14 March 2022 Pages: 445 - 454
Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort Paula SantiáAnna JansanaSURBCAN Group Epidemiology Open access 15 March 2022 Pages: 455 - 465
Trajectories of objectively measured physical function among older breast cancer survivors in comparison with cancer-free controls Juhua LuoStephen J. CarterMichael Hendryx Epidemiology 26 March 2022 Pages: 467 - 476
Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ Kristina M. JordahlKathleen E. MaloneChristopher I. Li Epidemiology 27 March 2022 Pages: 477 - 484
Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil Gabriela E. S. FelixRodrigo Santa Cruz GuindaliniOlufunmilayo I. Olopade Epidemiology Open access 30 March 2022 Pages: 485 - 494
Multivariate analysis of independent roles of socioeconomic status, occupational physical activity, reproductive factors, and postmenopausal hormonal therapy in risk of breast cancer Sushmita KatuwalJuha TapanainenEero Pukkala Epidemiology Open access 02 April 2022 Pages: 495 - 505
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis Adi PomerantzDaliah TsorefRinat Yerushalmi Epidemiology Open access 07 April 2022 Pages: 507 - 514
The clinical impact of MRI on surgical planning for patients with in-breast tumor recurrence Amanda SutherlandAshley HuppeKelsey E. Larson Epidemiology 12 April 2022 Pages: 515 - 522
HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome Faruk SkenderiMohamad Alhoda Mohamad AlahmadSemir Vranic Brief Communication Open access 30 March 2022 Pages: 523 - 533
